Ark Health (06086) rose by more than 11% at its peak, and as of the time of writing, it is up 7.26%, trading at 4.43 Hong Kong dollars, with a transaction volume of 53.9317 million Hong Kong dollars.
According to the Zhituo Finance APP, Ark Jianke (06086) rose over 11% at its peak, and as of the time of this report, it has risen by 7.26%, priced at 4.43 HKD, with a transaction volume of 53.9317 million HKD.
Recently, Ark Jianke appeared at the 2025 Greater Bay Area Hepatitis International Forum, where the Guangdong Provincial Liver Disease Research Institute awarded Ark Jianke the plaque of "AI+ Viral Hepatitis Prevention and Treatment Joint Training Base" at the hepatitis early prevention and treatment promotion conference. Both parties are cooperating to focus on the area of "AI+ Full Life Cycle Management of Liver Disease," empowering liver disease prevention and treatment with AI technology. According to Ark Jianke's first annual report since its listing, the company achieved annual revenue of 2.707 billion yuan, an increase of 11.2% year-on-year; the adjusted net income was 17.119 million yuan, a year-on-year increase of 139%. The number of registered users grew by 6.5 million to reach 49.2 million; monthly active users increased by 20% year-on-year to reach 10.1 million, leading the Internet chronic disease management vertical segment.
It is reported that Ark Jianke plans to focus on developing various "AI intelligent assistant" scenarios by 2025 to facilitate application implementation. The company will increase R&D investment, utilizing advanced large models like deepseek to extract the value of medical data, creating dedicated "digital employees" and "intelligent solutions" for the pharmaceutical industry, promoting the development of Digital Health towards a more professional, efficient, and intelligent direction. HTSC believes that AI is constructing a new paradigm in healthcare, and AI healthcare will have great prospects in 2025. The bank emphasizes that 2025 will usher in leapfrog development in "AI+ Healthcare," and related investment opportunities should be valued.
